西妥昔单抗联合同步放化疗用于局部晚期全喉鳞癌术后的疗效

目的探究西妥昔单抗联合同步放化疗用于局部晚期全喉鳞癌术后的治疗效果。方法选取局部晚期全喉鳞癌患者共86例,随机分为实验组(n=43)与对照组(n=43)。患者均接受全喉切除术,术后4周伤口愈合后,实验组给予西妥昔单抗联合同步放化疗治疗,对照组给予单纯同步放化疗。2组患者均治疗6周。治疗结束后,比较2组患者的卡氏(Karnofsky,KPS)评分、治疗期间死亡率、毒副作用发生率等。依据患者纳入本研究的时间,依次对患者进行60个月的随访,统计随访期间的死亡人数及对应的死亡时间及复发率,采用Kaplan-Meier法和对数秩检验(log-rank test)进行生存分析。结果与对照组相比,实验组患者的KPS评分显著提高(P<0.05)、复发率显著降低(P<0.05)。而2组治疗期间死亡率差异无统计学意义(P>0.05)。对照组与观察组患者血液学反应、消化系统反应、肝肾功能损害与总不良反应的发生率均无明显差异(P>0.05)。生存分析结果表明,相比于对照组,实验组患者的5年总生存率与生存时间均显著提高,差异具有统计学意义(χ^2=6.129,P=0.013)。结论相比于单纯同步放化疗,联合西妥昔单抗可提高治疗效果,并提高患者生存率,在临床上具有推广使用价值。

Cetuximab Combined with Concurrent Chemoradiotherapy for Postoperative Treatment of Locally Advanced Total Laryngeal Squamous Cell Carcinoma

Objective To explore the therapeutic effect of cetuximab combined with concurrent chemoradiotherapy on locally advanced total laryngeal squamous cell carcinoma.Methods 86 patients with advanced total laryngeal squamous cell carcinoma were randomly divided into combined group(n=43)and the control group(n=43).All patients underwent total laryngectomy.4 weeks after wound healing,the observation group was treated with cetuximab combined with concurrent chemoradiotherapy,while the control group was treated with concurrent chemoradiotherapy.Both groups were treated for 6 weeks.After the treatment,the Karnofsky(KPS)score,the mortality during treatment and the incidence of side effects were compared between the 2 groups.The patients were followed up for 60 months according to the time they were included in the study.The number of deaths,the corresponding time of death during the follow-up period and the recurrence rate were counted.Survival analysis was carried out by Kaplan-Meier method and log-rank test.Results Compared with the control group,the KPS score of the experimental group was significantly increased(P<0.05),and the recurrence rate was significantly lower(P<0.05).There was no significant difference in mortality between the two groups(P>0.05).There was no significant difference in the incidence of hematologic reaction,digestive system reaction,liver and kidney dysfunction and total adverse reactions between the control group and the observation group(P>0.05).Survival analysis showed that compared with the control group,the 5-year survival rate and survival time of patients in the observation group were significantly improved,with statistical significance(χ^2=6.129,P=0.013).Conclusion Compared with simple concurrent chemoradiotherapy,combined with cetuximab can improve the therapeutic effect and improve the survival rate of patients,which has the value of clinical application.